These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8229126)

  • 21. [The hematopoietic growth factor GM-CSF in chemotherapy for ovarian carcinoma].
    Biesma B; Willemse PH; Vellenga E; Limburg PC; Aalders JG; de Vries EG
    Ned Tijdschr Geneeskd; 1991 Mar; 135(10):420-4. PubMed ID: 2020314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.
    Lieschke GJ; Maher D; Cebon J; O'Connor M; Green M; Sheridan W; Boyd A; Rallings M; Bonnem E; Metcalf D
    Ann Intern Med; 1989 Mar; 110(5):357-64. PubMed ID: 2644886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
    Winter JN; Lazarus HM; Rademaker A; Villa M; Mangan C; Tallman M; Jahnke L; Gordon L; Newman S; Byrd K; Cooper BW; Horvath N; Crum E; Stadtmauer EA; Conklin E; Bauman A; Martin J; Goolsby C; Gerson SL; Bender J; O'Gorman M
    J Clin Oncol; 1996 Jan; 14(1):277-86. PubMed ID: 8558209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study.
    Edmonson JH; Suman VJ; Dalton RJ; Bro WC; Gallenberg MM; Long HJ; Levitt R; Hatfield AK; Krook JE; Mailliard JA; Gerstner JB;
    Cancer Invest; 2001; 19(6):597-602. PubMed ID: 11486702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
    Veldhuis GJ; Willemse PH; van Gameren MM; Aalders JG; Mulder NH; Mull B; Biesma B; de Vries EG
    J Clin Oncol; 1995 Mar; 13(3):733-40. PubMed ID: 7884433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.
    Goa KL; Bryson HM
    Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil.
    O'Reilly SE; Gelmon KA; Onetto N; Parente J; Rubinger M; Page RA; Plenderleith IH
    J Clin Oncol; 1993 Dec; 11(12):2411-6. PubMed ID: 8246030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors].
    Berthaud P; Eugène-Jolchine I; Spielmann M; Le Chevalier T; Tursz T
    Bull Cancer; 1993 May; 80(5):418-30. PubMed ID: 8173195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.
    Kohn EC; Sarosy G; Bicher A; Link C; Christian M; Steinberg SM; Rothenberg M; Adamo DO; Davis P; Ognibene FP
    J Natl Cancer Inst; 1994 Jan; 86(1):18-24. PubMed ID: 7505830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
    J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.
    Neidhart JA; Mangalik A; Stidley CA; Tebich SL; Sarmiento LE; Pfile JE; Oette DH; Oldham FB
    J Clin Oncol; 1992 Sep; 10(9):1460-9. PubMed ID: 1517789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GM-CSF, carboplatin, doxorubicin: a phase I study.
    Poplin EA; Alberts DS; Rinehart JJ; Smith HO; Neidhart JA; Hersh EM
    Cancer Chemother Pharmacol; 1994; 33(4):340-6. PubMed ID: 8281628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.
    Vadhan-Raj S; Kudelka AP; Garrison L; Gano J; Edwards CL; Freedman RS; Kavanagh JJ
    J Clin Oncol; 1994 Apr; 12(4):707-14. PubMed ID: 8151314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
    J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.
    Sarosy G; Kohn E; Stone DA; Rothenberg M; Jacob J; Adamo DO; Ognibene FP; Cunnion RE; Reed E
    J Clin Oncol; 1992 Jul; 10(7):1165-70. PubMed ID: 1376773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.
    Runowicz CD; Mandeli J; Speyer JL; Wadler S; Hochster H; Garrison L; Holland JF
    Am J Obstet Gynecol; 1996 Apr; 174(4):1151-9; discussion 1159-60. PubMed ID: 8623842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
    Fennelly D; Schneider J; Spriggs D; Bengala C; Hakes T; Reich L; Barakat R; Curtin J; Moore MA; Hoskins W
    J Clin Oncol; 1995 May; 13(5):1160-6. PubMed ID: 7537799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
    Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
    J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macrophage colony-stimulating factor enhances platelet recovery following cisplatin/carboplatin chemotherapy in ovarian cancer.
    Suzuki M; Ohwada M; Aida I; Sato I; Tamada T
    Gynecol Oncol; 1994 Jul; 54(1):23-6. PubMed ID: 8020834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.